Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Gent – page 14

907 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance
907
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

907 trials in Gent

Open in trial search

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Chronic graft versus host disease

Recruiting

Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Recruiting

Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Colitis microscopic

Recruiting

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Oesophageal adenocarcinoma

Recruiting

Study of zolbetuximab combined with paclitaxel and ramucirumab for patients with previously treated CLDN18.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zolbetuximab
  • Sponsor:UZ Leuven

Glomerulonephritis membranous+4

Recruiting

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Hypertriglyceridaemia

Recruiting

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

  • Influenza vaccine studies for adults 65+
  • RSV vaccine development
  • Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

  • Nasal decongestant dependency treatment
  • Chronic rhinosinusitis management
  • Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

  • Primary biliary cholangitis treatment
  • Psoriasis therapies
  • Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.